News - Pharmaceutical, AMAG Pharmaceuticals


Popular Filters

Licensing deals between Xenon and Isis for XEN701, and Access and AMAG for MuGard


USA-based Isis Pharmaceuticals (Nasdaq: ISIS) revealed that privately-held Canadian firm Xenon Pharmaceuticals…

Access PharmaceuticalsAMAG PharmaceuticalsIsis PharmaceuticalsLicensingMuGardNephrology and HepatologyOncologyPharmaceuticalXEN701Xenon Pharmaceuticals

Rainbow Coral seeks place in $84.6 billion biotechnology sector, forming new division; AMAG merger with Allos called off


Florida, USA-based Rainbow Coral (OTCQB: RBCC) last week announced its intention to move into the discovery…

Allos TherapeuticsAMAG PharmaceuticalsBiotechnologyMergers & AcquisitionsPharmaceuticalRainbow BiosciencesResearch

Allos looks to complete merger with AMAG, as third party bows out


Allos Therapeutics (Nasdaq: ALTH) says that it continues to work with fellow USA-based AMAG Pharmaceuticals…

Allos TherapeuticsAMAG PharmaceuticalsMergers & AcquisitionsPharmaceutical

US deal for Vectura; takeover bid for AMAG


There was good news this morning from Vectura Group (LSE: VEC), a UK-based inhalation product development…

Allos TherapeuticsAMAG PharmaceuticalsLicensingMergers & AcquisitionsPharmaceuticalRespiratory and PulmonaryVectura

AMAG Pharma and Allos Thera to merge in $686 million stock deal; Express Scripts to buy Medco


US drugmakers AMAG Pharmaceuticals (Nasdaq: AMAG) and Allos Therapeutics (Nasdaq: ALTH) entered into…

Allos TherapeuticsAMAG PharmaceuticalsBiotechnologyMergers & AcquisitionsPharmaceutical

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top